MLND News and Press, Millendo Therapeutics From 05/08/20

Millendo Therapeutics, Inc. (Nasdaq:MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended March 31, 2020. ...

Are These On Your List Of Penny Stocks To Watch In May 2020? Regardless of which names are on your list of penny stocks , this week will be an interesting one. While the coronavirus captivated headlines most of this year, China trade could be a focus for the broader markets. Last week, Pre...

Gainers:  Immunomedics (NASDAQ: IMMU )  +90% . More news on: Immunomedics, Inc., Akers Biosciences, Inc., Exantas Capital Corp., Stocks on the move, , Read more ...

Millendo Therapeutics (NASDAQ: MLND )  -69%  after livoletide flunks study. More news on: Millendo Therapeutics, Inc., Menlo Therapeutics Inc., BP Prudhoe Bay Royalty Trust, Stocks on the move, Read more ...

Thinly traded nano cap Millendo Therapeutics (NASDAQ: MLND ) slumps  69%  premarket on increased volume in reaction to unsuccessful results from a Phase 2b clinical trial evaluating lead drug livoletide in patients with Prader-Willi syndrome  (PWS), an inherited disorder ...

– Livoletide did not achieve statistically significant improvement in primary endpoint of change in hyperphagia and food-related behaviors relative to placebo – – Millendo to discontinue livoletide program in PWS and focus on development of pipeline assets nevanimi...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Millendo Therapeutics (NASDAQ: MLND ): FY GAAP EPS of -$3.25 misses by $0.06 . More news on: Millendo Therapeutics, Inc., Earnings news and commentary, , Read more ...

–Topline results from pivotal Phase 2b study of livoletide in patients with Prader-Willi syndrome (PWS) expected in early 2Q20– –Topline results from first cohort of Phase 2b study of nevanimibe in patients with classic congenital adrenal hyperplasia (CAH) expected...

Millendo Therapeutics (NASDAQ: MLND) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Yesterday, MLND appointed a new CMO only ~2 months away from the Phase 2b ZEPHYR data. With $48.3M in cash and $123M market cap, investors hav...